BioTuesdays
Pliant Therapeutics
Markets

Cantor starts Pliant Therapeutics at OW; PT $12

Cantor Fitzgerald launched coverage of Pliant Therapeutics (NASDAQ:PLRX) with an “overweight” rating and 12-month price target of $12. The stock closed at $4.93 on May 24. Pliant is developing novel therapies for...

May 25, 2022
Markets

Cantor starts Lyra Therapeutics at OW; PT $15

Cantor Fitzgerald initiated coverage of Lyra Therapeutics (NASDAQ:LYRA) with an “overweight” rating and price target of $15. The stock closed at $6.07 on May 23. Lyra is a clinical-stage company developing medicines...

May 24, 2022
MindMed
Executive Moves

MindMed names Schond Greenway as CFO

Schond Greenway Mind Medicine (NASDAQ:MNMD; NEO:MMED) appointed Schond Greenway as CFO. He comes to MindMed with more than 20 years of experience in investment banking, finance and corporate advisory, and investment...

May 24, 2022
HilleVax
Markets

Analysts start HilleVax at buy, outperform

Analysts for Stifel and SVB Securities initiated coverage of HilleVax (NASDAQ:HLVX) with “buy” and “outperform” ratings, and price targets of $34 and $30, respectively. The stock closed at $9.50 on May 23. The company’s...

May 24, 2022
Profound Medical
Developments

Profound Medical insiders add to holdings 

Profound Medical (NASDAQ:PROF; TSX:PRN) independent lead director, Brian Ellacott, and chairman and CEO, Arun Menawat, purchased additional shares of Profound on Nasdaq after the company’s 2022 first quarter blackout...

May 19, 2022
Humacyte
Markets

Piper cuts Humacyte to underweight; PT to $4 from $10

Piper Sandler downgraded Humacyte (NASDAQ:HUMA) to “underweight” from “overweight” and reduced its price target to $4 from $10, citing the sizable stock pullback in the sector. The stock closed at $5.37 on May 13. The...

May 16, 2022